{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:05:32Z","timestamp":1790399132736,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010908","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000}}],"reference-count":87,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010908.pub2","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T03:43:26Z","timestamp":1514951006000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Cyclophosphamide for connective tissue disease-associated interstitial lung disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Hayley","family":"Barnes","sequence":"first","affiliation":[{"name":"The Alfred Hospital; Department of Allergy, Immunology and Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E","family":"Holland","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Nutrition and Sport, School of Allied Health, La Trobe University; Discipline of Physiotherapy; Melbourne Victoria Australia 3086"},{"name":"The Alfred Hospital; Department of Physiotherapy; Melbourne Victoria Australia 3181"},{"name":"Austin Health; Institute for Breathing and Sleep; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen P","family":"Westall","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Allergy, Immunology and Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole SL","family":"Goh","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Allergy, Immunology and Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N","family":"Glaspole","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Allergy, Immunology and Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"10.1002\/14651858.CD010908.pub2-BIB0001|cit1","article-title":"A clinical trial of treatment for lung disease in scleroderma fibrosing alveolitis in scleroderma (FAST study)","author":"Herrick","year":"2005","journal-title":"National Research Register (UK)"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0002|cit2","unstructured":"Hoyles R Ellis R Herrick A Foley N McHugh N Pearson S Fibrosing alveolitis in scleroderma trial (FAST): a multicentre prospective randomised double blind placebo controlled trial [Abstract] British Thoracic Society Winter Meeting; 2005 December 7-9; London 2005 ii48"},{"issue":"12","key":"10.1002\/14651858.CD010908.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0004|cit4","unstructured":"Clements PJ Tashkin D Roth M Khanna D Furst DE Tseng CH The scleroderma lung study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSC) American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting; 2015 November 6-11; San Francisco 2015"},{"issue":"2 suppl 58","key":"10.1002\/14651858.CD010908.pub2-BIB0005|cit5","first-page":"S94","article-title":"Patients with systemic sclerosis (SSC) enrolled in the scleroderma lung study (SLS) have a high mortality within 5 years of stopping Cyclophosphamide (CYC)","volume":"28","author":"Furst","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD010908.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD010908.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","article-title":"Adverse events during the Scleroderma Lung Study","volume":"124","author":"Khanna","year":"2011","journal-title":"American Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010908.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD010908.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2015-208929","article-title":"Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment","volume":"75","author":"Kim","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Kim HJG Brown MS Goldin J Abtin FG Lynch DA Strollo D Cyclophosphamide treatment versus placebo in scleroderma lung study using total quantitative score of fibrosis, ground glass opacity, and honeycomb American Thoracic Society International Conference; 2010 May 14-19; New Orleans 2010","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2360"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0011|cit11","unstructured":"Tashkin DP Clements P Roth M Furst D Strange C Silver R Oral cyclophosphamide (CYC) vs placebo for treatment of scleroderma related interstitial lung disease (SSc ILD) main findings from the scleroderma lung study [Abstract] American Thoracic Society International Conference; 2006 May 19-21; San Diego 2006 A242 [Poster 818]"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0012|cit12","unstructured":"Tashkin DP Clements PJ Roth MD Furst DE Li N Chung J Two-year outcomes of one-year treatment with oral cyclophosphamide vs placebo for scleroderma-interstitial lung disease (SSc-ILD) [Abstract] American Thoracic Society International Conference; 2007 May 18-23; San Francisco 2007 [B91]"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010908.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010908.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.11-0801","article-title":"Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study","volume":"142","author":"Theodore","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Theodore AC Tseng CH Tashkin D Scleroderma Research Group Correlation of cough with disease activity and treatment with cyclosphosphamide in scleroderma interstitial lung disease [Abstract] American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2010 New Orleans, LA United States. American Thoracic Society 2010 A2362","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2362"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Khanna D Roth M Furst D Clements P Goldin J Arriola E Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (scleroderma lung study [SLS] II): rationale, design, methods, baseline characteristics and patient disposition Annals of the Rheumatic Diseases 2013","DOI":"10.1136\/annrheumdis-2013-eular.1523"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0018|cit18","article-title":"Mycophenolate vs oral cyclophosphamide in scleroderma interstitial lung disease (Scleroderma Lung Study II) [Protocol]","author":"Scleroderma Lung Study Research Group","journal-title":"www.sclerodermalungstudy.org\/ (accessed before 27 March 2017)"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Tashkin D Roth M Clements P Furst D Khanna D Goldin J Efficacy and safety of mycophenolate (MMF) vs oral cyclophosphamide (CYC) for treatment of Scleroderma-Interstitial Lung Disease (SscILD): results of Scleroderma Lung Study II Chest 2015","DOI":"10.1378\/chest.2331164"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0020|cit20","unstructured":"Tashkin DP Roth MD Clements PJ Furst DE Khanna D Kleerup EC Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (Scleroderma Lung Study [SLS] II): rationale, design, methods, baseline characteristics\/intercorrelations and patients American Thoracic Society International Conference; 2013 May 17-22; Philadelphia 2013 A2921"},{"issue":"9","key":"10.1002\/14651858.CD010908.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"708-19","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/annrheumdis-2015-eular.2081","article-title":"Cyclophosphamide versus mycophenolate for systemic sclerosis-related interstitial lung disease","volume":"74","author":"Volkmann","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0023|cit23","first-page":"suppl 10","article-title":"Safety and tolerability of cyclophosphamide versus mycophenolate for systemic sclerosis-related interstitial lung disease [abstract]","volume":"67","author":"Volkmann","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"45","key":"10.1002\/14651858.CD010908.pub2-BIB0024|cit24","first-page":"3641","article-title":"[Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease]","volume":"95","author":"Zhang","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"12","key":"10.1002\/14651858.CD010908.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.20320","article-title":"Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study","volume":"62","author":"Au","year":"2010","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0026|cit26","unstructured":"Choudhury SD Kundu S Ghosh S Agarwal R Paul S Hariprasath K Evaluation of pulse IV cyclophosphamide on scleroderma related interstitial lung disease: An Indian experience 46th Annual Conference of the Indian Pharmacological Society IPSCON 2013 16-20 Dec; Bangalore 2013 S107"},{"issue":"2","key":"10.1002\/14651858.CD010908.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD010908.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-005-0066-z","article-title":"Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study","volume":"7","author":"Highland","year":"2005","journal-title":"Current Rheumatology Reports"},{"issue":"2","key":"10.1002\/14651858.CD010908.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/art.20787","article-title":"Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study","volume":"52","author":"Khanna","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD010908.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial - Results from the scleroderma lung study","volume":"48","author":"Khanna","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0031|cit31","unstructured":"Kim H Goldin J Lynch D Strollo SD Ochs R Vasu F Cyclophosphamide versus placebo in Scleroderma Lung Study using quantitative lung fibrosis score [Abstract] American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008 A768"},{"issue":"12","key":"10.1002\/14651858.CD010908.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"Kim","year":"2011","journal-title":"European Radiology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Roth MD Tseng CH Clements PJ Furst DE Tashkin DP Goldin JG Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease American Thoracic Society International Conference; 2011 May 13-18; Denver 2011","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A3822"},{"issue":"1","key":"10.1002\/14651858.CD010908.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/rccm.200705-655OC","article-title":"Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease","volume":"177","author":"Strange","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Tashkin DP Elashoff D Roth MD Furst DE Khanna D Predictors of change in % predicted FVC over time in scleroderma (SSc) interstitial lung disease (ILD: findings from the Scleroderma Lung Study (SLS) [Abstract] American Thoracic Society International Conference; 2009 May 15-20 San Diego 2009 A3940","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A3940"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0036|cit36","unstructured":"Maher T Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD (RECITAL) NCT01862926"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0037|cit37","unstructured":"Mouthon L Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease (SCLEROCYC) NCT01570764 2016"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001, and by the ERS Executive Committee, June 2001","volume":"165","author":"American Thoracic Society (ATS)","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/ard.2007.075721","article-title":"The relationship of dyspnoea to function and quality of life in systemic sclerosis","volume":"67","author":"Baron","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010908.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1183\/09031936.00174910","article-title":"Significance of connective tissue disease features in idiopathic interstitial pneumonia","volume":"39","author":"Corte","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0045|cit45","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"Journal of Rheumatology"},{"issue":"2 suppl 58","key":"10.1002\/14651858.CD010908.pub2-BIB0049|cit49","first-page":"S94","article-title":"Patients with systemic sclerosis (SSC) enrolled in the Scleroderma Lung Study (SLS) have a high mortality within 5 years of stopping Cyclophosphamide (CYC)","volume":"28","author":"Furst","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1670-8","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0053|cit53","unstructured":"GRADE Working Group, McMaster University (developed by Evidence Prime) GRADEpro GDT 2015. Available from gradepro.org"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0055|cit55","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RCT.0b013e318181d551","article-title":"Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease","volume":"33","author":"Hwang","year":"2009","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"6","key":"10.1002\/14651858.CD010908.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD010908.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2005.050187","article-title":"Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study","volume":"65","author":"Khanna","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD010908.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Khanna D Denton CP Jahreis A van Laar JM Cheng S Spotswood H Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the faSScinate trial Annals of the Rheumatic Diseases 2015 87 8","DOI":"10.1136\/annrheumdis-2015-eular.2281"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD010908.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2015-208929","article-title":"Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment","volume":"75","author":"Kim","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0064|cit64","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clinical Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/labinvest.2010.73","article-title":"Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype","volume":"90","author":"Mathai","year":"2010","journal-title":"Laboratory Investigation"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010908.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2009.02.009","article-title":"Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease","volume":"103","author":"Mittoo","year":"2009","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biocel.2010.10.013","article-title":"TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P","volume":"43","author":"Murray","year":"2011","journal-title":"International Journal of Biochemistry and Cell Biology"},{"issue":"5","key":"10.1002\/14651858.CD010908.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","article-title":"Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis","volume":"71","author":"Nathan","year":"2016","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0071|cit71","unstructured":"NCT02597933 A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosis clinicaltrials.gov\/ct2\/show\/NCT02597933"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0072|cit72","unstructured":"NCT02745145 Abituzumab in SSc-ILD ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0073|cit73","unstructured":"NCT02808871 Phase ll study of pirfenidone in patients with RAILD clinicaltrials.gov\/ct2\/show\/NCT02808871"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1755-1536-4-12","article-title":"Local apoptosis promotes collagen production by monocyte-derived cells in transforming growth factor beta1-induced lung fibrosis","volume":"4","author":"Peng","year":"2011","journal-title":"Fibrogenesis and Tissue Repair"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0077|cit77","unstructured":"Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration Review Manager (RevMan) Version 5.3 2014"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1378\/chest.08-2572","article-title":"Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia","volume":"136","author":"Song","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/thoraxjnl-2012-201786","article-title":"Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis","volume":"68","author":"Stock","year":"2013","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD010908.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010908.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1745-6215-8-38","article-title":"OMERACT: an international initiative to improve outcome measurement in rheumatology","volume":"8","author":"Tugwell","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1164\/ajrccm.149.6.8004317","article-title":"Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis","volume":"149","author":"Wells","year":"1994","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2008.101691","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Wells","year":"2008","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010908.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"728-39","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease - mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nature Reviews. Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010908.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","author":"Glaspole","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010908.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T10:12:45Z","timestamp":1751191965000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010908.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010908.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}